Caplacizumab (His Tag)
Based on 1 publication(s) in Google Scholar
Caplacizumab (His Tag) is a humanized anti-von Willebrand factor (vWF) nanobody. Caplacizumab (His Tag) inhibits the binding of vWF with platelet glycoprotein (GP) Ibα. Caplacizumab (His Tag) inhibits the vWF-mediated platelet adhesion and prevents further microthrombi formation. Caplacizumab (His Tag) can be used for the research of thrombotic thrombocytopenic purpura (TTP).
For research use only. We do not sell to patients.
- Purity: ≥99.0%
- CAS No.: 915810-67-2
- Molecular Weight:29 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Caplacizumab (His Tag)
More
Biological Activity
VH-VH
Human
VWF
Caplacizumab (His Tag) inhibits the binding of VWF with platelet glycoprotein (GP) Ibα in blood specimens[2].
Caplacizumab (His Tag) (0.8 μg/mL) can completely inhibit platelet adhesion to the collagen surface at high shear rates (>1500 s-1)[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Caplacizumab (His Tag) (at plasma levels between 0.3-0.5 μg/mL, i.v. bolus) shows a strong antithrombotic effect in a modified Folts model in baboons[4].
Caplacizumab (His Tag) (5 mg/kg total dose with intravenous and subcutaneous injection; intravenous injection first and subcutaneous injections follow) prevents middle cerebral artery thrombosis in a guinea pig model of middle cerebral artery thrombosis, and reduces brain damage without inducing hemorrhage[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Guinea pig (Dunkin-Hartley, male, 350-400 g) model of middle cerebral artery thrombosis[5]
-
Dosage:5 mg/kg total dose (0.4 mg/kg intravenously + 1.6 mg/kg subcutaneously at time 0 followed by 3 mg/kg subcutaneously 6 h later)
-
Administration:Intravenous injection first and subcutaneous injections follow
-
Result:Prevented thrombosis when administered immediately after and 15 min after complete occlusion of the middle cerebral artery.
Reduced brain damage area and did not increase intracerebral hemorrhage.
Reduced microvascular thrombosis in the ischemic brain tissue.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
VH-VH
ELISA, FACS, Functional assay
-
Immobilized Human VWF-A1 (1260–1554aa)-Fc can bind Caplacizumab. The EC50 for this effect is 7.442 ng/mL.
Chemical Information
-
CAS No. 915810-67-2
-
Appearance Liquid
-
Molecular Weight 29 kDa
-
Color Colorless to light yellow
-
SMILES
[Caplacizumab (His Tag)]
-
Synonyms
ALX-0681; ALX-0081
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Purity & Documentation
-
Data Sheet (264 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Maëlle le Besnerais, et al. Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment. Expert Opin Biol Ther. 2019 Nov;19(11):1127-1134. [Content Brief]
[3]. Callewaert F, et al. Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. Blood. 2012 Oct 25;120(17):3603-10. [Content Brief]
[4]. Ulrichts H, et al. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood. 2011 Jul 21;118(3):757-65. [Content Brief]
[5]. Momi S, et al. Reperfusion of cerebral artery thrombosis by the GPIb-VWF blockade with the Nanobody ALX-0081 reduces brain infarct size in guinea pigs. Blood. 2013 Jun 20;121(25):5088-97. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz